Crossject Cash Flow Conversion Efficiency

Latest as of December 2025: 0.640x

Crossject cash flow conversion efficiency. Based on the latest financial reports, Crossject (ALCJ) has a cash flow conversion efficiency ratio of 0.640x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.12 Million ≈ $-3.64 Million USD) by net assets (€-4.87 Million ≈ $-5.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Crossject (2012–2025)

Cash flow conversion efficiency of Crossject from 2012 to 2025. This chart illustrates how Crossject's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Crossject (ALCJ) share price today for real-time trading data and today's change.

Crossject Cash Flow Conversion Ratio Explained

Crossject cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Crossject Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Crossject ranked by their cash flow conversion efficiency. Also see Crossject stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
MAISON POMMERY & ASSOCIES PA:POMRY	-0.065x
Inoue Rubber (Thailand) Public Company Limited BK:IRC	0.056x
Moda-InnoChips Co. Ltd KQ:080420	-0.018x
Manba Finance Ltd NSE:MANBA	-0.483x
Erbud SA WAR:ERB	-0.262x
Kilitch Drugs (India) Limited NSE:KILITCH	-0.025x
POLARIS WORKS Inc KQ:123010	0.019x
PolyPid NASDAQ:PYPD	-2.876x

Annual Cash Flow Conversion Efficiency for Crossject (2012–2025)

The table below shows the annual cash flow conversion efficiency of Crossject from 2012 to 2025. Review Crossject free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€-4.87 Million ≈ $-5.69 Million	€-6.35 Million ≈ $-7.42 Million	1.304x	-56.19%
2024-12-31	€-2.67 Million ≈ $-3.13 Million	€-7.96 Million ≈ $-9.30 Million	2.977x	+152.94%
2023-12-31	€-5.27 Million ≈ $-6.16 Million	€-6.20 Million ≈ $-7.25 Million	1.177x	+162.23%
2022-12-31	€2.69 Million ≈ $3.14 Million	€-5.08 Million ≈ $-5.94 Million	-1.891x	-270.39%
2021-12-31	€-5.48 Million ≈ $-6.41 Million	€-6.08 Million ≈ $-7.11 Million	1.110x	-77.03%
2020-12-31	€-1.13 Million ≈ $-1.32 Million	€-5.46 Million ≈ $-6.39 Million	4.833x	+364.36%
2019-12-31	€3.01 Million ≈ $3.52 Million	€-5.51 Million ≈ $-6.44 Million	-1.828x	+62.27%
2018-12-31	€1.65 Million ≈ $1.93 Million	€-8.02 Million ≈ $-9.37 Million	-4.845x	-492.85%
2017-12-31	€6.09 Million ≈ $7.11 Million	€-4.97 Million ≈ $-5.82 Million	-0.817x	-16.62%
2016-12-31	€6.28 Million ≈ $7.35 Million	€-4.40 Million ≈ $-5.15 Million	-0.701x	-28.56%
2015-12-31	€8.80 Million ≈ $10.29 Million	€-4.80 Million ≈ $-5.61 Million	-0.545x	-149.64%
2014-12-31	€14.48 Million ≈ $16.93 Million	€-3.16 Million ≈ $-3.70 Million	-0.218x	+78.53%
2013-12-31	€947.65K ≈ $1.11 Million	€-964.00K ≈ $-1.13 Million	-1.017x	-440.48%
2012-12-31	€-1.90 Million ≈ $-2.23 Million	€-569.06K ≈ $-665.29K	0.299x	--

About Crossject

PA:ALCJ France Medical Instruments & Supplies

Market Cap

$77.81 Million

€66.56 Million EUR

Market Cap Rank

#20013 Global

#308 in France

Share Price

€1.25

Change (1 day)

-1.11%

52-Week Range

€1.25 - €2.69

All Time High

€10.40